Carisma Therapeutics’ chimeric antigen receptor (CAR) macrophage CT-0508 has continued to be well-tolerated in patients with solid tumors, with promising signs of efficacy, according to updated data from a phase 1, first-in-human trial...
Leaders from four young Philadelphia-area companies focused on developing new ways to treat cancer describe the challenges they face, from finding consistent sources of funding to worries over manufacturing costs.
Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the...
CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) macrophage therapy by Carisma Therapeutics is being evaluated in a phase 1, first-in-human study (NCT04660929) for safety and tolerability in...